

### **Remarks**

A new claim (3) has been added. With new claim 3, applicants further elect a specific disorder for further prosecution, wherein the specific disorder involves defective binding of the leukocytes to activated platelets or endothelial cells, as supported and enabled on page 42, ¶88 of the specification.

Should any fees be required, the Commissioner is hereby authorized to charge to Credit card as shown on the attached credit card information authorization form PTO-2038.

### **Conclusion**

This is believed to be a complete response to the Notice mailed September 21, 2006.

It is respectfully submitted that the application is now in a condition for examination.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Christopher W. Corbett', is written over a horizontal line.

Christopher W. Corbett, Ph.D.  
Reg. No. 36,109  
DUNLAP & CODDING, P.C.  
P.O. Box 16370  
Oklahoma City, OK 73113  
Telephone: (405) 607-8600  
Facsimile: (405) 607/8686

Agent for Applicant(s)

In the Claims:

1. (Cancelled)
2. A method of detecting a disorder involving defective binding of P-selectin glycoprotein ligand in a patient, comprising:  
  
providing an antibody to a protein component or to a carbohydrate-protein component of P-selectin glycoprotein ligand, the glycoprotein ligand comprising a fucosylated sialylated glycoprotein containing sialyl Lewis<sup>x</sup> antigen and the glycoprotein ligand having an apparent relative molecular weight of about 120,000 D as assessed by SDS-PAGE under reducing conditions and wherein the antibody has binding specific for P-selectin glycoprotein ligand and wherein the antibody inhibits binding of P-selectin glycoprotein ligand to P-selectin; and  
  
testing the binding of the antibody to leukocytes obtained from the patient.
3. (New) The method of claim 2 wherein the disorder involves defective binding of leukocytes to activated platelets or endothelial cells.